Cancer Research The Future of Cancer Research: Science and Patient Impact AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 68, 4013-4017, June 1, 2008. doi: 10.1158/0008-5472.CAN-07-3324
© 2008 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by May, K. A.
Right arrow Articles by Khuri, F. R.
PubMed
Right arrow Articles by May, K. A.
Right arrow Articles by Khuri, F. R.
Related Collections
Right arrow Therapeutics and Targets
Right arrow Therapeutics and Targets: Drug Mechanisms and Resistance
Right arrow Clinical Research
Right arrow Clinical Research: Clinical Trials

Reviews

Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion

Kelly A. May and Fadlo R. Khuri

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

Requests for reprints: Fadlo R. Khuri, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322. Phone: 404-778-4250; E-mail: fkhuri{at}emory.edu.

Key Words: erythropoietin • darbepoetin • biological mechanisms • solid tumors

Erythropoietin-stimulating agents (ESA) are approved for use in treating chemotherapy-induced anemia in patients with nonmyeloid malignancies. However, recent clinical trials have shown evidence of inferior overall survival and/or locoregional control of tumors in patients receiving ESAs. Given these concerning data, current studies are focused on elucidating the biological mechanisms by which ESAs may contribute to cancer promotion. Evidence suggests that ESAs activate several signaling pathways that are important in altering tumor behavior and response to treatment. Although further research is needed to more precisely elucidate these mechanisms, caution should be exercised in the use of ESAs beyond their approved indication in cancer patients. [Cancer Res 2008;68(11):4013–7]




This article has been cited by other articles:


Home page
 CRO ContentHome page
G. C. Prendergast
Translational Research: Speeding New Concepts between Lab and Clinic
Cancer Reviews Online Content, July 1, 2008; 2008(7): 13 - 14.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.